Imlifidase, also known by its development code IDE‑S and marketed under the name Idefir, is a recombinant enzyme derived from the IgG‑degrading enzyme of Streptococcus pyogenes. It specifically cleaves human immunoglobulin G (IgG) molecules at the lower hinge region, producing F(ab')₂ and Fc fragments, thereby rapidly reducing circulating IgG levels.
Mechanism of action
The enzyme catalyzes proteolysis of the IgG hinge region, resulting in the loss of Fc-mediated immune functions such as complement activation and binding to Fcγ receptors. By transiently depleting IgG, imlifidase can diminish pathogenic alloantibody activity.
Therapeutic applications
Imlifidase has been investigated primarily for:
- Desensitization in organ transplantation – It enables highly sensitized kidney‑transplant candidates, who possess high levels of donor‑specific anti‑HLA antibodies, to receive compatible grafts by reducing antibody titres pre‑transplant.
- Treatment of antibody‑mediated rejection (AMR) – Rapid IgG clearance can mitigate ongoing humoral injury to transplanted organs.
- Potential use in autoimmune conditions – Theoretical application in diseases driven by pathogenic IgG antibodies, though clinical data are limited.
Clinical development
Phase II and Phase III clinical trials have evaluated safety, pharmacodynamics, and efficacy in renal transplantation settings. Results demonstrated:
- A prompt reduction of total IgG levels by >95 % within hours of administration.
- Significant lowering of donor‑specific antibody titres, facilitating transplantation in patients previously unsuitable for surgery.
- A generally favorable safety profile, with transient infections and mild infusion‑related reactions being the most common adverse events.
Regulatory status
As of 2024, imlifidase has received marketing authorization in the European Union for the desensitization of highly sensitized adult patients undergoing kidney transplantation. Regulatory review in other jurisdictions, including the United States, is ongoing.
Pharmacokinetics
Following a single intravenous infusion, imlifidase exhibits rapid distribution and a short plasma half‑life (approximately 30–45 minutes), after which IgG levels recover over several weeks as new antibodies are synthesized.
Manufacturing
The enzyme is produced using recombinant DNA technology in a mammalian cell expression system, ensuring proper folding and activity. Quality control includes assays for enzymatic activity, purity, and absence of bacterial contaminants.
Safety considerations
Because imlifidase broadly depletes IgG, patients are at increased risk for bacterial and viral infections during the period of IgG nadir. Prophylactic antimicrobial strategies and monitoring of immunoglobulin levels are recommended. The enzyme does not affect other immunoglobulin classes (IgM, IgA, IgE) or circulating albumin.
Research outlook
Ongoing studies are exploring dosing regimens, combination with other immunosuppressive agents, and potential utility in non‑transplant antibody‑mediated diseases. Long‑term follow‑up data are being collected to assess durability of desensitization and impact on graft survival.
